Skip to content
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · MID CAP

OrthoPediatrics Corp. KIDS

11 fiscal years on record · USD · FY2025 reported · SEC filings only
$236.3M
▲ 15.4% YoY
$-39.6M
$-16.0M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

OrthoPediatrics Corp. designs, develops and markets anatomically appropriate implants, instruments and specialized braces for children with orthopedic conditions. It sells its specialized products, including PediLoc, PediPlates, the ApiFix Mid-C System and Boston Brace 3D bracing products, to hospitals and medical facilities throughout the United States and various international markets, using a contract manufacturing model for implants and related surgical instrumentation while manufacturing its orthopedic bracing products in-house. The company also operates multiple orthotic and prosthetic clinics that deliver pediatric non-surgical O&P treatment. As of December 31, 2025, the company and its subsidiaries had 602 full-time equivalent employees. It sells its products in over 75 countries outside of the United States. For the years ended December 31, 2025, 2024 and 2023, its revenue was $236.3 million, $204.7 million and $148.7 million, respectively. OrthoPediatrics Corp. was initially organized as an Indiana limited liability company on August 31, 2006, and was converted to a Delaware corporation on November 30, 2007.

Written from the business description in ORTHOPEDIATRICS CORP's annual report to the U.S. Securities and Exchange Commission, filed 4 March 2026. Every sentence was checked against that document before publication.

Growth

USD 236.3M
Revenue, FY2025 · full 11-year series below
Revenue $M Net income $M
FY2025 · Revenue 236.3 · Net income -39.6
100M200M-15M-30M
20152018202120242025
Compound annual growth
+24.6%
+27.2%
+22.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +27.2% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−17 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -16.6% · Net -16.8%
-20%-40%
201520202025
ROE
FY2025 · ROE -11.3%
-5%-10%-15%
201520202025
Three returns, three denominators.

Each USD of equity lost 11 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -16.0
-20M-40M
201520202025
Net buybacks $M Dividends $M
FY2019 · Dividends 0.0 · Net buybacks ·
2.5M5.0M
20152016201720182019

Total assetsUSD 508.6M
EquityUSD 346.6M
CashUSD 19.6M
Gross debtUSD 101.7M
Net debtUSD 82.1M
Current ratio5.55×

Net debt stands at 24% of equity.

The 11-year record

11 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
KIDS, 11-year financial record
Metric 20252024202320222021202020192018201720162015
Revenue $B0.20.20.10.10.10.10.10.10.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.0−0.0−0.0−0.0−0.0−0.00.00.00.00.00.0
Net income $B−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−1.69−1.64−0.920.06−0.84−1.82−0.94−0.96−5.86−7.14−7.27
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌
Payout %——————−0−0−67−0−0
ROE %−11.3−10.3−5.60.4−7.1−17.5−12.3−18.6———
Shares out B0.030.020.020.020.020.020.020.010.010.00◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 53 reconciliationsAUDITED

Reconciled in 11 of the 11 fiscal years we could check. 18 checks were skipped: the balance sheet is not tagged before 2016. Eight checks were skipped: EPS is not tagged before 2015. Eight checks were skipped: revenue is not tagged before 2015.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsDecember 31
Data on record since2015

Share this section

Download image